Harry Paul Erba, MD, PhD

Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address harry.erba@duke.edu

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Education and Training

  • Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
  • Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
  • Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
  • Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
  • Ph.D., Stanford University, 1988
  • M.D., Stanford University School of Medicine, 1988

Publications

LeBlanc, TW, and Erba, HP. "Shifting paradigms in the treatment of older adults with AML." Seminars in Hematology 56, no. 2 (April 2019): 110-117. (Review)

PMID
30926086
Full Text

Medeiros, BC, Othus, M, Tallman, MS, Sun, Z, Fernandez, HF, Rowe, JM, Lazarus, HM, Appelbaum, FR, Luger, SM, Litzow, MR, and Erba, HP. "The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)." Leukemia Research 78 (March 2019): 29-33.

PMID
30673620
Full Text

Othus, M, Estey, EH, Garcia-Manero, G, Wood, BL, Stirewalt, DL, Godwin, JE, Weick, JK, Anderson, JE, Appelbaum, FR, Erba, HP, and Walter, RB. "Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials." Leukemia 33, no. 2 (February 2019): 554-558.

PMID
30315233
Full Text

Othus, M, Sekeres, MA, Nand, S, Garcia-Manero, G, Appelbaum, FR, Erba, HP, and Estey, E. "Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies." Leukemia 33, no. 2 (February 2019): 371-378.

PMID
30315234
Full Text

Woyach, JA, Ruppert, AS, Heerema, NA, Zhao, W, Booth, AM, Ding, W, Bartlett, NL, Brander, DM, Barr, PM, Rogers, KA, Parikh, SA, Coutre, S, Hurria, A, Brown, JR, Lozanski, G, Blachly, JS, Ozer, HG, Major-Elechi, B, Fruth, B, Nattam, S, Larson, RA, Erba, H, Litzow, M, Owen, C, Kuzma, C, Abramson, JS, Little, RF, Smith, SE, Stone, RM, Mandrekar, SJ, and Byrd, JC. "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL." The New England Journal of Medicine 379, no. 26 (December 2018): 2517-2528.

PMID
30501481
Full Text

Halpern, AB, Othus, M, Huebner, EM, Scott, BL, Becker, PS, Percival, M-EM, Hendrie, PC, Gardner, KM, Chen, TL, Buckley, SA, Orlowski, KF, Anwar, A, Appelbaum, FR, Erba, HP, Estey, EH, and Walter, RB. "Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms." Leukemia 32, no. 11 (November 2018): 2352-2362.

PMID
29720734
Full Text

Jamy, O, Bae, S, Costa, LJ, Erba, HP, and Papadantonakis, N. "Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow." Leukemia Research 74 (November 2018): 64-67.

PMID
30300822
Full Text

DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, Swords, R, Collins, RH, Mannis, GN, Pollyea, DA, Donnellan, W, Fathi, AT, Pigneux, A, Erba, HP, Prince, GT, Stein, AS, Uy, GL, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Willekens, C, Choe, S, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Yang, H, Dai, D, Fan, B, Goldwasser, M, Liu, H, Agresta, S, Wu, B, Attar, EC, Tallman, MS, Stone, RM, and Kantarjian, HM. "Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.": CIG MEDIA GROUP, LP, September 1, 2018.

Full Text

Fathi, AT, Erba, HP, Lancet, JE, Stein, EM, Ravandi, F, Faderl, S, Walter, RB, Advani, AS, DeAngelo, DJ, Kovacsovics, TJ, Jillella, A, Bixby, D, Levy, MY, O'Meara, MM, Ho, PA, Voellinger, J, and Stein, AS. "A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML." Blood 132, no. 11 (September 2018): 1125-1133.

PMID
30045838
Full Text

DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, Swords, R, Collins, RH, Mannis, GN, Pollyea, DA, Donnellan, W, Fathi, AT, Pigneux, A, Erba, HP, Prince, GT, Stein, AS, Uy, GL, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Willekens, C, Choe, S, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Yang, H, Dai, D, Fan, B, Goldwasser, M, Liu, H, Agresta, S, Wu, B, Attar, EC, Tallman, MS, Stone, RM, and Kantarjian, HM. "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML." The New England Journal of Medicine 378, no. 25 (June 2, 2018): 2386-2398.

PMID
29860938
Full Text

Pages